Ignite Creation Date:
2024-05-06 @ 11:23 AM
Last Modification Date:
2024-10-26 @ 12:44 PM
Study NCT ID:
NCT03504163
Status:
RECRUITING
Last Update Posted:
2024-06-25
First Post:
2018-04-11
Brief Title:
Pembrolizumab MK-3475 and Bacillus Calmette-Guérin BCG as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer NMIBC and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma NMI-UTUC
Sponsor:
Organization:
Memorial Sloan Kettering Cancer Center
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
37
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: